Key Points
- CEO George Lemaitre sold 18,600 shares of LeMaitre Vascular on May 7 at an average price of $107.64, totaling about $2.0 million. After the sale, he still owned 1,457,900 shares, and the transaction reduced his stake by 1.26%.
- LeMaitre Vascular posted solid quarterly results, reporting EPS of $0.68 versus the $0.66 estimate and revenue of $66.55 million, with sales up 11.1% year over year. The company also issued FY 2026 EPS guidance of $2.93 to $3.08.
- The company announced a quarterly dividend of $0.25 per share, payable June 4 to shareholders of record on May 21. That equals a $1.00 annualized dividend and a yield of about 1.0%.
LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) insider Trent Kamke sold 2,928 shares of the business's stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the sale, the insider owned 3,749 shares in the company, valued at approximately $401,143. This trade represents a 43.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
LeMaitre Vascular Stock Performance
NASDAQ:LMAT opened at $101.64 on Tuesday. The stock has a market cap of $2.32 billion, a P/E ratio of 37.51, a price-to-earnings-growth ratio of 3.00 and a beta of 0.60. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The stock's 50-day moving average is $110.09 and its 200-day moving average is $94.71. LeMaitre Vascular, Inc. has a 1-year low of $78.35 and a 1-year high of $118.01.
LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. The company had revenue of $66.55 million for the quarter, compared to analysts' expectations of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The business's quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities research analysts anticipate that LeMaitre Vascular, Inc. will post 3 earnings per share for the current year.
LeMaitre Vascular Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Thursday, May 21st. LeMaitre Vascular's payout ratio is 36.90%.
Institutional Trading of LeMaitre Vascular
Several institutional investors have recently added to or reduced their stakes in LMAT. M&T Bank Corp boosted its holdings in LeMaitre Vascular by 2,240.5% in the fourth quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier's stock valued at $32,283,000 after acquiring an additional 381,061 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in LeMaitre Vascular by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier's stock valued at $31,731,000 after acquiring an additional 231,157 shares during the last quarter. First Trust Advisors LP boosted its holdings in LeMaitre Vascular by 35.4% in the third quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier's stock valued at $72,541,000 after acquiring an additional 216,919 shares during the last quarter. Bessemer Group Inc. lifted its stake in LeMaitre Vascular by 292.3% in the first quarter. Bessemer Group Inc. now owns 171,838 shares of the medical instruments supplier's stock valued at $18,759,000 after buying an additional 128,033 shares during the period. Finally, Millennium Management LLC lifted its stake in LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier's stock valued at $17,722,000 after buying an additional 115,141 shares during the period. 84.64% of the stock is currently owned by institutional investors.
Key LeMaitre Vascular News
Here are the key news stories impacting LeMaitre Vascular this week:
- Positive Sentiment: LeMaitre recently reported better-than-expected quarterly EPS of $0.68, beating estimates, with revenue up 11.1% year over year. LeMaitre Vascular stock report
- Positive Sentiment: The company also raised guidance for fiscal 2026, which supports the longer-term growth outlook. LeMaitre Vascular stock report
- Neutral Sentiment: LeMaitre announced a quarterly dividend of $0.25 per share, reinforcing its cash-generating profile but likely not a major short-term stock driver. LeMaitre Vascular stock report
- Negative Sentiment: CEO George W. Lemaitre sold 27,881 shares and 18,600 shares in separate transactions, a pattern that may be weighing on sentiment. Article: LeMaitre Vascular CEO George Lemaitre Sells 27,881 Shares Article: LeMaitre Vascular CEO George Lemaitre Sells 18,600 Shares of Stock
- Negative Sentiment: Additional insider sales by Bridget A. Ross and Trent G. Kamke add to the impression that management is trimming exposure. Article: George Lemaitre Sells 18,600 Shares of LeMaitre Vascular Stock
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on the company. Roth Mkm restated a "buy" rating and set a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Freedom Capital upgraded LeMaitre Vascular to a "hold" rating in a report on Tuesday, March 31st. Citizens Jmp upped their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the company a "market outperform" rating in a report on Wednesday, May 6th. Wall Street Zen upgraded LeMaitre Vascular from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. Finally, Weiss Ratings cut LeMaitre Vascular from a "buy (b)" rating to a "buy (b-)" rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $112.60.
Read Our Latest Stock Report on LeMaitre Vascular
About LeMaitre Vascular
(
Get Free Report)
LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.
Founded in 1983 by George D.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
